Both in Pharmaceuticals
UroGen Pharma vs Rapport Therapeutics
Over the past year URGN returned +45.1% and RAPP returned −2.7%; their daily moves had a correlation of 0.17.
URGN +45.1% RAPP −2.7%Growth of $1, one year, split-adjusted
| Metric | URGN | RAPP |
|---|---|---|
| Price | $28.74 | $25.93 |
| Market cap | $1.40B | $1.46B |
| Today | −16.45% | +1.93% |
| 1 month | −30.6% | −16.8% |
| 6 months | +9.5% | −30.0% |
| Year to date | +22.7% | −14.5% |
| 1 year | +39.4% | −3.7% |
| Revenue growth (YoY) | +199.2% | — |
| Gross margin | 90.9% | — |
| Net margin | −19.8% | — |
| P/E (TTM) | — | — |
| Price / sales | 7.4× | 73.0× |
| Net cash | -$85.1M | $436.1M |
| Dividend yield | — | — |
| Volatility (60d) | 54.9% | 79.1% |
| Short % of float | 12.3% | 10.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).